February 23, 2017—Safety-net healthcare providers need a clear strategy and focused action to oppose drug industry efforts to dismantle the 340B drug discount program, two 340B hospital leaders argue in a new peer-reviewed professional journal on leadership, administration, and management in healthcare. … [Read more...]
Bill Would Make More School-Based Health Centers 340B-Eligible
February 21, 2017—Members of Congress have reintroduced legislation to make more school-based health centers eligible for 340B drug discounts. … [Read more...]
Tom Price Takes Helm at Health and Human Services
Rep. Tom Price (R-Ga.) was confirmed today to be Secretary of Health and Human Services. Dr. Price earned his medical degree from the University of Michigan, did his surgical residency at Emory University and served as medical director of the Orthopedic Clinic at Grady Memorial Hospital in Atlanta. All are 340B providers. … [Read more...]
HHS Withdraws 340B Mega-guidance
January 31, 2017—The Department of Health and Human and Human Services has withdrawn the final 340B program mega-guidance from White House review. The Office of Budget and Management announced the action on its Reginfo.gov website. On Jan. 20, the Trump Administration asked all federal departments and agencies to freeze pending regulations and guidance documents – presumably … [Read more...]
Senator Slams CMS Response to Questions About EpiPen
January 26, 2017—Sen. Chuck Grassley (R-Iowa) is ramping up pressure on the Centers for Medicare and Medicaid Services to hand over documents about Mylan Pharmaceuticals’ misclassification of EpiPen as a generic drug and subsequent underpayment of Medicaid rebates. … [Read more...]
Trump Administration Freezes Regulations, Presumably Including 340B Mega-guidance
January 25, 2017—The Trump administration has asked federal departments and agencies to freeze pending regulations and guidance documents – presumably including the 340B mega-guidance – for review by an administration appointee or designee. Incoming administrations commonly embargo the preceding presidency’s newest and planned rules. … [Read more...]
Studies Lift Lid on Drug Industry Influence Peddling
January 18, 2017—Patient advocacy groups and private practice oncologists frequently parrot the drug industry about the 340B drug discount program. New research in JAMA Internal Medicine sheds light on why that might be. … [Read more...]